Cary Street Partners Investment Advisory’s Takeda Pharmaceutical TAK Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-687	Closed	-$10.6K	–	1678
2023 Q3	$10.6K	Hold	687	–	–	﹤0.01%	1284
2023 Q2	$10.8K	Hold	687	–	–	﹤0.01%	1222
2023 Q1	$11.3K	Sell	687 -4	-0.6%	-$64	﹤0.01%	1114
2022 Q4	$10.8K	Buy	+691	New	+$9.65K	﹤0.01%	1134
2020 Q4	–	Sell	-115	Closed	-$2K	–	808
2020 Q3	$2K	Buy	+115	New	+$2.09K	﹤0.01%	924

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Cary Street Partners Investment Advisory's TAK Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 687 shares — an estimated $10.6K sold.

Cary Street Partners Investment Advisory first reported a position in TAK in Q3 2020 and held it in 5 quarters. The position peaked at $11.3K in Q1 2023. 307 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 687 Takeda Pharmaceutical shares in Q4 2023, an estimated $10.6K.
Cary Street Partners Investment Advisory first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 5 quarters.
Cary Street Partners Investment Advisory's Takeda Pharmaceutical position peaked at $11.3K in Q1 2023.
307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.